Yüklüyor......
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
BACKGROUND: Postmarketing commitments are clinical studies that pharmaceutical companies agree to conduct at the time of FDA approval, but which are not required by statute or regulation. As FDA increasingly adopts a lifecycle evaluation process, greater emphasis will be placed on postmarket evidenc...
Kaydedildi:
| Yayımlandı: | BMC Med |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6572730/ https://ncbi.nlm.nih.gov/pubmed/31203816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-019-1344-3 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|